114 related articles for article (PubMed ID: 36396062)
1. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model.
Gao SJ; Jin L; Meadows HW; Shafman TD; Gross CP; Yu JB; Aerts HJWL; Miccio JA; Stahl JM; Mak RH; Decker RH; Kann BH
J Thorac Oncol; 2023 Mar; 18(3):339-349. PubMed ID: 36396062
[TBL] [Abstract][Full Text] [Related]
2. The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.
Duijm M; Oomen-de Hoop E; van Voort van der Zyp N; van de Vaart P; Tekatli H; Hoogeman M; Senan S; Nuyttens J
Radiother Oncol; 2021 Mar; 156():223-230. PubMed ID: 33418006
[TBL] [Abstract][Full Text] [Related]
3. Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer.
Baker S; Bakunina K; Duijm M; Hoogeman MS; Cornelissen R; Antonisse I; Praag J; Heemsbergen WD; Nuyttens JJ
Radiat Oncol; 2020 Apr; 15(1):89. PubMed ID: 32321553
[TBL] [Abstract][Full Text] [Related]
4. Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms.
Zindler JD; Jochems A; Lagerwaard FJ; Beumer R; Troost EGC; Eekers DBP; Compter I; van der Toorn PP; Essers M; Oei B; Hurkmans CW; Bruynzeel AME; Bosmans G; Swinnen A; Leijenaar RTH; Lambin P
Radiother Oncol; 2017 May; 123(2):189-194. PubMed ID: 28237400
[TBL] [Abstract][Full Text] [Related]
5. Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Ye L; Shi S; Zeng Z; Huang Y; Hu Y; He J
Jpn J Clin Oncol; 2018 Feb; 48(2):160-166. PubMed ID: 29253245
[TBL] [Abstract][Full Text] [Related]
6. Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath-hold CT images with random survival forest: A multi-institutional study.
Kakino R; Nakamura M; Mitsuyoshi T; Shintani T; Kokubo M; Negoro Y; Fushiki M; Ogura M; Itasaka S; Yamauchi C; Otsu S; Sakamoto T; Sakamoto M; Araki N; Hirashima H; Adachi T; Matsuo Y; Mizowaki T
Med Phys; 2020 Sep; 47(9):4634-4643. PubMed ID: 32645224
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
8. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
[TBL] [Abstract][Full Text] [Related]
9. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease.
Tanadini-Lang S; Rieber J; Filippi AR; Fode MM; Streblow J; Adebahr S; Andratschke N; Blanck O; Boda-Heggemann J; Duma M; Eble MJ; Ernst I; Flentje M; Gerum S; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lohaus F; Petersen C; Schrade E; Wendt TG; Wittig A; Høyer M; Ricardi U; Sterzing F; Guckenberger M
Radiother Oncol; 2017 May; 123(2):182-188. PubMed ID: 28169042
[TBL] [Abstract][Full Text] [Related]
10. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
11. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.
Callegaro D; Miceli R; Bonvalot S; Ferguson P; Strauss DC; Levy A; Griffin A; Hayes AJ; Stacchiotti S; Pechoux CL; Smith MJ; Fiore M; Dei Tos AP; Smith HG; Mariani L; Wunder JS; Pollock RE; Casali PG; Gronchi A
Lancet Oncol; 2016 May; 17(5):671-80. PubMed ID: 27068860
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Wong JK; Shaikh T; DeMora L; Zhang E; Borghaei H; Hayes SB; Kumar S; Meyer JE; Hallman MA
Am J Clin Oncol; 2020 Apr; 43(4):243-248. PubMed ID: 31913907
[TBL] [Abstract][Full Text] [Related]
13. Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience.
Fischer-Valuck BW; Boggs H; Katz S; Durci M; Acharya S; Rosen LR
Tumori; 2015; 101(3):287-93. PubMed ID: 25908031
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Stages I to IIA Non-Small-Cell Lung Cancer.
Miller CJ; Martin B; Stang K; Hutten R; Alite F; Small C; Emami B; Harkenrider MM
Clin Lung Cancer; 2019 Jan; 20(1):37-42. PubMed ID: 30279109
[TBL] [Abstract][Full Text] [Related]
15. Multi-institutional dose-segmented dosiomic analysis for predicting radiation pneumonitis after lung stereotactic body radiation therapy.
Adachi T; Nakamura M; Shintani T; Mitsuyoshi T; Kakino R; Ogata T; Ono T; Tanabe H; Kokubo M; Sakamoto T; Matsuo Y; Mizowaki T
Med Phys; 2021 Apr; 48(4):1781-1791. PubMed ID: 33576510
[TBL] [Abstract][Full Text] [Related]
16. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?
Diamant A; Chatterjee A; Faria S; Naqa IE; Bahig H; Filion E; Robinson C; Al-Halabi H; Seuntjens J
Radiother Oncol; 2018 Sep; 128(3):513-519. PubMed ID: 29801721
[TBL] [Abstract][Full Text] [Related]
17. External Validation and Optimization of the SPRING Model for Prediction of Survival After Surgical Treatment of Bone Metastases of the Extremities.
Sørensen MS; Gerds TA; Hindsø K; Petersen MM
Clin Orthop Relat Res; 2018 Aug; 476(8):1591-1599. PubMed ID: 30020148
[TBL] [Abstract][Full Text] [Related]
18. Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters.
Zhou Z; Folkert M; Cannon N; Iyengar P; Westover K; Zhang Y; Choy H; Timmerman R; Yan J; Xie XJ; Jiang S; Wang J
Radiother Oncol; 2016 Jun; 119(3):501-4. PubMed ID: 27156652
[TBL] [Abstract][Full Text] [Related]
19. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
